Last year we covered the Glove Tricorder, a non-invasive, glove-based technology developed by AugMI Labs (Augmented Medical Intelligence Labs). Briefly, the glove uses advanced tactile technology and data analytics to quantify, digitize and analyze important physical exam parameters in the setting of telemedicine. Founded by two Harvard Medical School students, the glove has undergone several revisions in its new prototype. The medical glove allows for assessment of vital parameters on the fingertips of the user (blood pressure, pulse, and oxygen saturation) as well as parameters related to emergency illness, including blood flow. The Glove Tricorder stores-and-forwards as well as streams all data wirelessly through integration with existing electronic medical records (EMRs). This allows AugMI to provide real-time information to doctors as a tool to proactively manage outpatient health remotely.
Recently, AugMI labs won the Thomson Reuters Data Prize at the MIT $100K Entrepreneurship Competition. The Data Prize rewards innovative uses of big and linked data, and encourages entrepreneurs of the future to assess how data can be used to enhance their businesses.
We had a chance to speak with Marc Succi, who along with Andrew Bishara and Fransiska Putri Wina Hadiwidjana co-founded AugMI Labs, about the new product. According to Marc:
We are very grateful to MIT and Thomson Reuters for this award, the funds of which will be used to further build and refine our backend software structure while preparing for pilot trials…The core feature of the product is real-time data streaming and storage to enable data-driven clinical decision making. Though many advancements have been made in evidence-based medicine in reference to populations, the uniqueness of each patient poses nuances and variables on the treating physician. With our device in the home, patients will be able to easily, intuitively, and constantly monitor their condition. Data is streamed to our secure, HIPAA-compliant servers and to both physician and patient portals. We can trend the data over time to establish a baseline state for the patient, enabling us to alert the user of any abnormal or emergent changes in condition. This has immediate implications in clinical decision making. In the future, we will be able to anonymously correlate risk factors, condition progression and outcomes on a mass scale, enabling a large variety of clinical outcomes research to be performed on our consumer population in order to advance evidence-based medicine.
Company Website: AugMI Labs…
Press Release: AugMI Labs wins the Thomson Reuters Data Prize…